Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

CSPC Pharmaceutical’s Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First‑Line Advanced Breast Cancer – HER2 Bispecific Combo Advances in China

Fineline Cube Aug 19, 2026
Company Drug

Betta Pharmaceuticals Partner EyePoint Reports EYP‑1901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD – DURAVYU Fails Non‑Inferiority vs. Aflibercept

Fineline Cube Aug 19, 2026
Company Drug

Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer

Fineline Cube Feb 4, 2026

AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration...

Company Drug

Bayer Nubeqa Gets NMPA Approval for Metastatic Prostate Cancer

Fineline Cube Feb 4, 2026

Bayer AG (ETR: BAYN) announced that the National Medical Products Administration (NMPA) has approved Nubeqa (darolutamide)...

Company

Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data

Fineline Cube Feb 4, 2026

Daiichi Sankyo (TYO: 4568) announced it has discontinued internal development of DS-9606, a Claudin 6 (CLDN6)-targeting...

Company Deals

Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone

Fineline Cube Feb 3, 2026

Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study...

Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Fineline Cube Feb 3, 2026

PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immuno‑inflammation biotech founded in 2016, made an initial public...

Company Medical Device

Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA

Fineline Cube Feb 3, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the U.S. Food and Drug Administration...

Company Deals

Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis

Fineline Cube Feb 3, 2026

Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive...

Company Medical Device

ZEISS ARTEVO Gets NMPA Approval for China Ophthalmology Market

Fineline Cube Feb 3, 2026

ZEISS Medical Technology announced that the National Medical Products Administration (NMPA) has approved the ARTEVO...

Company Drug

Venglustat Gaucher: Sanofi Meets Primary Endpoint in Phase 3 LEAP2MONO Study

Fineline Cube Feb 3, 2026

Sanofi (NASDAQ: SNY) announced positive results from the LEAP2MONO phase 3 study (NCT05222906), showing venglustat met the...

Company Deals

Arctic Vision-Mdco Technology Merger Builds Ophthalmology Platform

Fineline Cube Feb 3, 2026

Arctic Vision, a China‑based ophthalmology specialist, and Mdco Technology Co., Ltd. have agreed to integrate...

Company

Eli Lilly to Invest $3.5B in Pennsylvania Plant for Retatrutide Production

Fineline Cube Feb 3, 2026

Eli Lilly (NYSE: LLY) announced plans to invest more than USD 3.5 billion in a new manufacturing facility...

Company Drug

Eli Lilly Mounjaro Fails to Win EU Approval for HFpEF Heart Failure Indication

Fineline Cube Feb 3, 2026

Eli Lilly (NYSE: LLY) announced that the European Medicines Agency (EMA) drug advisory panel declined to...

Company Drug

Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation

Fineline Cube Feb 3, 2026

AstraZeneca (AZ, NASDAQ: AZN) announced that the Committee for Medicinal Products for Human Use (CHMP) has...

Company Drug

Chiesi’s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China

Fineline Cube Feb 3, 2026

Chiesi Group’s China unit announced that the National Medical Products Administration (NMPA) has granted marketing...

Company Deals

SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal

Fineline Cube Feb 3, 2026

SanegeneBio, a Suzhou‑based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a...

Company Deals

Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership

Fineline Cube Feb 3, 2026

Zonsen Peplib Biotech Inc., a China‑based polypeptide lead compound developer, announced a collaboration with Eli...

Company Drug

Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis

Fineline Cube Feb 3, 2026

Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved Cosentyx (secukinumab) for...

Company Deals

WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases

Fineline Cube Feb 3, 2026

WuXi Biologics (HKG: 2269) announced a partnership with Vertex Pharmaceuticals for an innovative trispecific T‑cell engager...

Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026

The National Medical Products Administration (NMPA) released the 101st batch of reference drugs for generic...

Company Deals

Zenshine Pharma Files for Hong Kong IPO with $357M Valuation

Fineline Cube Feb 2, 2026

Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main...

Posts pagination

1 … 91 92 93 … 709

Recent updates

  • CSPC Pharmaceutical’s Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First‑Line Advanced Breast Cancer – HER2 Bispecific Combo Advances in China
  • Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306
  • Betta Pharmaceuticals Partner EyePoint Reports EYP‑1901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD – DURAVYU Fails Non‑Inferiority vs. Aflibercept
  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical’s Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First‑Line Advanced Breast Cancer – HER2 Bispecific Combo Advances in China

Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Company Drug

Betta Pharmaceuticals Partner EyePoint Reports EYP‑1901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD – DURAVYU Fails Non‑Inferiority vs. Aflibercept

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.